Hormone Therapy Overview for the Behavioral Health Provider. Julie Thompson, PA Fenway Health

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Hormone Therapy Overview for the Behavioral Health Provider. Julie Thompson, PA Fenway Health"

Transcription

1 Hormone Therapy Overview for the Behavioral Health Provider Julie Thompson, PA Fenway Health

2 Continuing Medical Education Disclosure Program Faculty: Julie Thompson, PA Current Position: Physician s Assistant, Fenway Health Disclosures: No relevant financial relationships. All hormone therapy for transgender people is off-label. It is the policy of The National LGBT Health Education Center, Fenway Health that all CME planning committee/faculty/authors/editors/staff disclose relationships with commercial entities upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflicts of interest and, if identified, they are resolved prior to confirmation of participation. Only participants who have no conflict of interest or who agree to an identified resolution process prior to their participation were involved in this CME activity.

3 Hormone Readiness

4 WPATH Criteria for Initiating Hormone Therapy Persistent, well-documented gender dysphoria Capacity to make a fully informed decision and consent to treatment Age of majority in a given country If significant medical or mental health concerns are present, they must be reasonably well-controlled

5 Informed Consent Model Effectively communicate benefits, risks and alternatives of treatment to patient Judge that the patient is able to understand and consent to the treatment Informed consent model does not preclude mental health care Based on clinical judgment Lack of contraindications Pt. capacity to give informed consent Pt with clear understanding of information they are consenting to expectations, knowns, unknowns

6 Initial Visits Reviewing implications and obtaining consent: Reproductive Rights - freezing sperm/eggs, ability to get pregnant despite testosterone therapy Permanent vs transient changes Goals of short-term and long-term Short and long-term risks, screenings unknowns! Social implications supports job/career sex

7 Hormone Therapy

8 FTM Hormone Therapy

9 Female to Male Treatment Options Injectable Testosterone Testosterone Enanthate or Cypionate Transdermal Testosterone Androderm Topical testosterone Gels in packets and pumps, multiple formulations (Testim, Androgel) Axiron 2% pump gel for axillary application 1 pump to each axilla daily Testosterone Pellet Testopel- implant q 3 to 6 months

10 Female to Male Treatment Options

11 Masculinizing Effects of Testosterone Effect Onset (months) Maximum (years) Skin oiliness/acne Fat redistribution Cessation of Menses 2-6 Clitoral enlargement Vaginal atrophy Emotional changes Increased sex drive

12 Masculinizing Effects of Testosterone Effect Onset (months) Maximum (years) Deepening of voice Facial/Body Hair Growth Scalp Hair Loss 6-12 Increased Muscle Mass & Strength Coarser Skin/ Increased Sweating Weight Gain/Fluid Retention Mild Breast Atrophy Weakening of Tendons

13 Other Treatment Therapies for FTM Testosterone cream in Aquaphor for clitoral enlargement Estrogen vaginal cream for atrophy Rogaine or Finasteride for male pattern baldness Use of Progesterone aid in cessation of menses before or after starting testosterone therapy LARC for cessation of menses/birth control

14 MTF Hormone Therapy

15 Male to Female Treatment Options Antiandrogens Spironolactone (aldactone) Finasteride (Proscar) Oral Estrogens Estradiol (estrace) Premarin (conjugated estrogens) Transdermal Estrogens Estradiol patch, twice weekly Injectable Estrogens Estradiol valerate 5-20mg IM q2 weeks Estradiol cypionate 2-10mg IM weekly

16 Feminizing Effects of Estrogens and Anti-Androgens Effect Onset (months) Maximum (months) Decreased Libido Decreased Spontaneous Erections Breast Growth Decreased Testicular Volume Decreased Sperm Production Unknown Unknown Redistribution of Body Fat Decrease in Muscle Mass Softening of Skin 3-6 Unknown Decreased Terminal Hair 6-12 >36

17 Cosmetic Therapies Hydroquinone Topical treatment for pigmentation caused by estrogen therapy Hair Removal Eflornithine (Vaniqa) cream Electrolysis Laser hair removal

18 Physical Implications and Risks

19 Risks of Estrogen Therapy Venous thrombosis/thromboembolism Weight gain Decreased libido Increased triglycerides Elevated blood pressure Decreased glucose tolerance /risk of diabetes Gallbladder disease Benign pituitary prolactinoma Breast cancer(?) Infertility

20 Health Considerations for the Trans Feminine Spectrum Thrombosis/Blood clots Rates of 1 to 6% reported Associated with cigarette smoking and immobility (surgery) Type of anti-androgen and estrogen used (ethinyl estradiol)

21 Health Considerations for the Trans Feminine Spectrum Cardiovascular disease About 50 to 60% higher risk in transwomen Associated with smoking and higher baseline cholesterol levels Higher rates of diabetes may play a role Type of estrogen used

22 Risks of Testosterone Therapy Lower HDL Elevated triglycerides Increased homocysteine levels Hepatotoxicity? Polycythemia Unknown effects on breast, endometrial, ovarian tissues Increased risk of sleep apnea (Insulin resistance) Infertility

23 Health Considerations for Trans Masculine Spectrum Polycythemia/ increase in red blood cells?risk of blood clots, heart attacks and strokes Dosage and form of testosterone used

24 Good News No increase in the incidence of cancers in transwomen or transmen.

25 Risks of Hormone Therapy 2011 review of Dutch patient cohort 966 transwomen and 365 transmen 50% higher mortality rate in MTF patients compared to general population Most of the increase in mortality was due to higher rates of suicide, drug-related deaths, and AIDS The mortality rate for trans men was similar to the general population

26 Mental Health Implications

27 Mental Health Issues Estrogens can potentially worsen depression Testosterone may destabilize bipolar disorder, schizophrenia, impulse control disorders

28 Mental Health Benefit Access to cross-sex hormone therapy has been reported in a number of studies to be associated with better functioning in terms of : gender dysphoria relief quality of life improvement psychological functioning decrease in suicide attempts improve body image

29 Depression and Suicide Weighing risks and benefits: Well-controlled BH issues vs Harm Reduction and Baseline functioning Suicide rates: In some surveys, up to 40% of transgender/gender variant individuals report having ATTEMPTED suicide. Suicidal ideation rates as high as 64% A 2009 NYC Metro survey of 571 transwomen found a lifetime history of suicidal thinking of approximately 53%, suicidal planning of approximately 35%, and attempted suicide rate of 28 35%

30 Depression and Suicide A 2009 study of 515 transgender individuals in San Francisco found that depression approaches 62% in trans women and 55% in trans men NYC metropolitan area survey found that 52 54% of trans women have a lifetime history of major depression

31 Depression and Suicide ** But, suicide rates remain higher than in the general population even after hormones or surgery. Minority Stress Discrimination Expectations not met

32 Additional Topics in Hormone Therapy

33 Options for Non-binary Identified People Lower doses? Shorter courses? Testosterone blockers alone? What are the risks of stopping hormone therapy?

34 Questions?

35 Resources UCSF Center of Excellence for Transgender Health Guidelines Vancouver Coastal Health Guidelines The Endocrine Society Guidelines (First published September, 2009) Transsexual-Persons.pdf Transline Surgical options:

HEALTH CARE FOR TRANSGENDER PERSONS

HEALTH CARE FOR TRANSGENDER PERSONS HEALTH CARE FOR TRANSGENDER PERSONS Tim Cavanaugh, MD Medical Director for the Trans Health Program Fenway Health 1 TRANSGENDER refers to a person who is born with the genetic traits of one gender but

More information

INFORMED CONSENT FOR FEMINIZING HORMONE THERAPY

INFORMED CONSENT FOR FEMINIZING HORMONE THERAPY INFORMED CONSENT FOR FEMINIZING HORMONE THERAPY The use of hormone therapy for gender transition/affirmation is based on many years of experience treating trans persons. Research on hormone therapy is

More information

Endocrinology and the Transgender Patient

Endocrinology and the Transgender Patient Endocrinology and the Transgender Patient Matthew Leinung MD Professor of Medicine Albany Medical College This project is supported by the Health Resources and Services Administration (HRSA) of the U.S.

More information

Questions of Definition

Questions of Definition Gender & Sex Questions of Definition What is a person s sex versus a person s gender? [Do they, can they, differ?] Sociological versus biological definitions: Sex is more biological. male/female (i.e.,

More information

GENder Education and Care Interdisciplinary Support (GENECIS) Feminizing Medications for Patients with Gender Dysphoria

GENder Education and Care Interdisciplinary Support (GENECIS) Feminizing Medications for Patients with Gender Dysphoria GENder Education and Care Interdisciplinary Support (GENECIS) Feminizing Medications for Patients with Gender Dysphoria Patient Information and Informed Consent and Assent for Minors Before using medications

More information

Informed Consent Form for Feminizing Medications

Informed Consent Form for Feminizing Medications Student Health Services Oregon State University, 201 Plageman Building, Corvallis, Oregon 97331-8567 Tel 541-737-9355 General Fax 541-737-4530 Medical Fax 541-737-9665 http://studenthealth.oregonstate.edu/

More information

Client Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS

Client Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS Client Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS Before using medications to transition and feminize, you need to know the possible advantages, disadvantages and risks

More information

Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients

Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008

More information

Reproductive Health and Obstetric Care in Transgender Patients. Rebekah P. Viloria, MD Obstetrician & Gynecologist Fenway Health

Reproductive Health and Obstetric Care in Transgender Patients. Rebekah P. Viloria, MD Obstetrician & Gynecologist Fenway Health Reproductive Health and Obstetric Care in Transgender Patients Rebekah P. Viloria, MD Obstetrician & Gynecologist Fenway Health Continuing Medical Education Disclosure Program Faculty: Rebekah P. Viloria,

More information

Transgender Populations

Transgender Populations Treating HIV in Transgender Patients: A Clinical Update Tonia Poteat, PhD, MPH, PA-C Physician Assistant, JHMI Assistant Professor, JHSPH 18 November 2016 Transgender Populations Transgender (trans): people

More information

Pharmacy Policy. Adult transgender hormonal therapy may be approved when all of the following criteria are met:

Pharmacy Policy. Adult transgender hormonal therapy may be approved when all of the following criteria are met: Pharmacy Policy Class: Transgender Hormonal Treatment for Adults Line of Business: Medi-Cal Effective date: February 15, 2017 Revision date: February 15, 2017 This policy has been developed through review

More information

A Guide to Feminizing Hormones Gender Affirming Care

A Guide to Feminizing Hormones Gender Affirming Care Patient and Family Education A Guide to Feminizing Hormones Gender Affirming Care Hormone therapy is an option that can help transgender people feel more comfortable in their bodies. Like other medical

More information

Clinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:

Clinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: Clinical Policy: (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 07.25.17 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder

More information

A Guide to Masculinizing Hormones Gender Affirming Care

A Guide to Masculinizing Hormones Gender Affirming Care Patient and Family Education A Guide to Masculinizing Hormones Gender Affirming Care Hormone therapy is an option that can help transgender people feel more comfortable in their bodies. Like other medical

More information

Primary and HIV Care for Our Transgender Patients

Primary and HIV Care for Our Transgender Patients Primary and HIV Care for Our Transgender Patients James Hekman, MD FACP AAHIVS Clinical Assistant Professor Community Internal Medicine CWRU/Cleveland Clinic. Who are our TG patients? Demographics Those

More information

The Transgender Patient and Medications

The Transgender Patient and Medications The Transgender Patient and Medications Deb Thorp, MD Medical Director Park Nicollet Gender Services Clinic Dr. Thorp indicated no potential conflict of interest to this presentation. She does intend to

More information

Polycystic Ovary Syndrome

Polycystic Ovary Syndrome Polycystic Ovary Syndrome Polycystic ovary syndrome (PCOS) is common. It can cause period problems, reduced fertility, excess hair growth, and acne. Many women with PCOS are also overweight. Treatment

More information

Androderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo

Androderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical

More information

Transgender Treatment in High Risk Adolescents

Transgender Treatment in High Risk Adolescents Transgender Treatment in High Risk Adolescents Jeffrey M. Birnbaum 1,2, MD, MPH, Jennifer E. Lee, MPH 1, Jonovia Chase 1, Betsy Eastwood 3, PhD 1 Department of Pediatrics & Public Health/SUNY Downstate

More information

What is PCOS? PCOS THE CONQUER PCOS E-BOOK. You'll be amazed when you read this...

What is PCOS? PCOS THE CONQUER PCOS E-BOOK. You'll be amazed when you read this... PCOS What is PCOS? You'll be amazed when you read this... What is PCOS?. Who is at risk? How to get tested? What are the complications. Is there a cure? What are the right ways to eat? What lifestyle changes

More information

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society

More information

Class Review: Cross sex Hormone Therapy

Class Review: Cross sex Hormone Therapy Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND

Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND 7% of all women 18-45 Obesity 1/3 of all US women Incidence of PCOS is increasing with increase obesity Obesity Irregular

More information

F REQUENTLY A SKED Q UESTIONS

F REQUENTLY A SKED Q UESTIONS Polycystic heart, blood vessels, and appearance. Women with PCOS have these characteristics: Ovarian high levels of male hormones, also called androgens an irregular or no menstrual cycle Syndrome may

More information

About PCOS. About PCOS

About PCOS. About PCOS About PCOS About PCOS Polycystic Ovarian Syndrome (PCOS) is the most common hormonal reproductive problem in women of childbearing age. It can affect a woman s menstrual cycle, fertility, hormones, insulin

More information

Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None

Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone

More information

Case 5:12-cv M Document 118 Filed 07/31/14 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF OKLAHOMA

Case 5:12-cv M Document 118 Filed 07/31/14 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF OKLAHOMA Case 5:12-cv-01065-M Document 118 Filed 07/31/14 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF OKLAHOMA FILED Ms. Ronny Darnell. ) a.k.a: Ms. Phoebe Renee Halliwell, ) Plaintiff,

More information

Reference ID:

Reference ID: Medication Guide ANDROGEL (AN DROW JEL) CIII (testosterone gel) 1% Read this Medication Guide that comes with ANDROGEL 1% before you start taking it and each time you get a refill. There may be new information.

More information

MEDICAL POLICY No R1 GENDER REASSIGNMENT SURGERY

MEDICAL POLICY No R1 GENDER REASSIGNMENT SURGERY GENDER REASSIGNMENT SURGERY Effective Date: January 1, 2017* Review Dates: 8/15, 8/16, 11/16 Date Of Origin: August 12, 2015 Status: Current *Note: For fully funded commercial (individual or group), this

More information

ANDROGEN DEFICIENCY Update on Evaluation and Management

ANDROGEN DEFICIENCY Update on Evaluation and Management ANDROGEN DEFICIENCY Update on Evaluation and Management Kristen Gill Hairston, MD, MPH Associate Professor of Internal Medicine Section of Endocrinology and Metabolism Wake Forest University School of

More information

Accession #: Patient: Jane Doe Convert to pdf, Save or PRINT >> ADRENAL CHECK

Accession #: Patient: Jane Doe Convert to pdf, Save or PRINT >> ADRENAL CHECK Page 1 of 5 Patient: Jane Doe Tel: (123) 456-7890 Email: test@test.com Sex: Female Age: 36 yr Date of Birth: 1980-12-12 Height: 5 ft 0 in Weight: 135 lbs Waist size: 30 in 1st day of last menses: Day 07,

More information

5. Summary of Data Reported and Evaluation

5. Summary of Data Reported and Evaluation 326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal

More information

Late onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital

Late onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,

More information

Test Results SB Samples Arrived: 01/15/2014 Samples Collected: Saliva: 01/11/14 07:14 Date Closed: 01/18/2014

Test Results SB Samples Arrived: 01/15/2014 Samples Collected: Saliva: 01/11/14 07:14 Date Closed: 01/18/2014 Test Results 8605 SW Creekside Place Beaverton, OR 97008 Phone: 503-466-2445 Fax: 503-466-1636 info@zrtlab.com www.zrtlab.com 2014 01 15 001 SB Samples Arrived: 01/15/2014 Samples Collected: Saliva: 01/11/14

More information

Testosterone Therapy in Men An update

Testosterone Therapy in Men An update Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None

More information

6/14/2010. GnRH=Gonadotropin-Releasing Hormone.

6/14/2010. GnRH=Gonadotropin-Releasing Hormone. Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression

More information

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research

More information

Where are the injections given? They are given in the upper outer hip.

Where are the injections given? They are given in the upper outer hip. 1 How do you diagnose low Testosterone in men? Low Testosterone can be diagnosed if you have 3 or more of the following symptoms: lack of libido fatigue insomnia erectile dysfunction (ED) depression loss

More information

Providing Transgender- Affirming Primary Care By Allison Fox, FNP, RN, BA and Margot Presley, FNP, MN-RN, BA, DNP-S

Providing Transgender- Affirming Primary Care By Allison Fox, FNP, RN, BA and Margot Presley, FNP, MN-RN, BA, DNP-S Providing Transgender- Affirming Primary Care By Allison Fox, FNP, RN, BA and Margot Presley, FNP, MN-RN, BA, DNP-S Lecture Objectives Care Coverage in OR and the US Best-practice customer service Hormones:

More information

Testosterone Injection and Implant

Testosterone Injection and Implant Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone

More information

HRT & Menopause Where Do We Stand Now?

HRT & Menopause Where Do We Stand Now? HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by

More information

A Systematic Review of the Effects of Hormone Therapy on Psychological Functioning and Quality of Life in Transgender Individuals

A Systematic Review of the Effects of Hormone Therapy on Psychological Functioning and Quality of Life in Transgender Individuals Transgender Health Volume 1.1, 2016 DOI: 10.1089/trgh.2015.0008 Transgender Health REVIEW ARTICLE Open Access A Systematic Review of the Effects of Hormone Therapy on Psychological Functioning and Quality

More information

A Systematic Review of the Effects of Hormone Therapy on Psychological Functioning and Quality of Life in Transgender Individuals

A Systematic Review of the Effects of Hormone Therapy on Psychological Functioning and Quality of Life in Transgender Individuals A Systematic Review of the Effects of Hormone Therapy on Psychological Functioning and Quality of Life in Transgender Individuals The Harvard community has made this article openly available. Please share

More information

Cancer in the LGBTQ Community. Katie Imborek, MD Clinical Assistant Professor University of Iowa Department of Family Medicine

Cancer in the LGBTQ Community. Katie Imborek, MD Clinical Assistant Professor University of Iowa Department of Family Medicine + Cancer in the LGBTQ Community Katie Imborek, MD Clinical Assistant Professor University of Iowa Department of Family Medicine + Objectives Discuss the possible reasons that LGBTQ people have a disproportionate

More information

Topic 24: Estrogens and Female Reproductive Drugs

Topic 24: Estrogens and Female Reproductive Drugs Topic 24: Estrogens and Female Reproductive Drugs I. Contraceptives A. Estrogen-Progestin Contraceptives Note all of these drugs contain one estrogen (listed first) and one progestin Drug to know: ethinyl

More information

Sex! Woo Hoo! Finally something interesting!

Sex! Woo Hoo! Finally something interesting! Sex! Woo Hoo! Finally something interesting! Males: born with Primary Sex Characteristics like a penis, testes, a scrotum, and a prostate Females: Primary Sex Characteristics include a vagina, a uterus,

More information

22/09/2014. Menopause Management. Menopause. Menopause symptoms

22/09/2014. Menopause Management. Menopause. Menopause symptoms Menopause Management Dr Sonia Davison Jean Hailes for Women s Health Menopause Time of last menstrual period - average age 51 Premature Menopause: occurs before age 40 Perimenopause (menopause transition):

More information

in Primary Care (Part 2) Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University

in Primary Care (Part 2) Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University Common Endocrine Problems Seen in Primary Care (Part 2) Lecture #34 Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University None Conflict of Interest Topics to be Covered

More information

Pharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting Disclosure

Pharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting Disclosure Pharmacology Update: Menopause and Hormone Therapy North American Menopause Society Meeting 2015 Disclosure The faculty and planners for this activity, as well as the CME staff, do not have any relevant

More information

Bioidentical Hormones: Just the Facts

Bioidentical Hormones: Just the Facts Bioidentical Hormones: Just the Facts Melissa McNeil, MD, MPH Professor of Medicine and Obstetrics, Gynecology and Reproductive Sciences Chief, Section of Women s Health University of Pittsburgh Disclosures!

More information

Androgen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital

Androgen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Androgen deficiency Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Outline Pathological androgen deficiency - Background, causes, interpretation - Indications for treatment Androgen

More information

Point-Counterpoint: Late Onset Hypogonadism (LOH)

Point-Counterpoint: Late Onset Hypogonadism (LOH) Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx

More information

One Day Hormone Check

One Day Hormone Check One Day Hormone Check Patient: EMILY TEST DOB: January 18, 1948 Sex: F MRN: 0000000004 Order Number: J5070009 Completed: March 07, 2014 Received: March 07, 2014 Collected: March 07, 2014 Alec Smart, ND

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Testosterone Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 7 References... 7 Effective Date... 1/1/2018

More information

Female Sexual Hormones Indications and Therapy

Female Sexual Hormones Indications and Therapy Female Sexual Hormones Indications and Therapy In puberty, a woman has about 400,000 ovules, at the age of 40-44 years about 17,000 only. On average, each grown-up woman (still having ovulation) loses

More information

Menopause - a summary of management

Menopause - a summary of management Page 1 of 5 Menopause - a summary of management Original article by: May Su Resources Menopause treatment algorithm The Jean Hales Foundation for women's heath. Menopause, a treatment algorithm. (Australian

More information

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date:

Clinical Policy: Goserelin Acetate (Zoladex) Reference Number: ERX.SPA.145 Effective Date: Clinical Policy: (Zoladex) Reference Number: ERX.SPA.145 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Menopause and HIV. Together, we can change the course of the HIV epidemic one woman at a time.

Menopause and HIV. Together, we can change the course of the HIV epidemic one woman at a time. Menopause and HIV Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Menopause? Menopause: Point in time when a woman's menstrual periods

More information

10 Essential Blood Tests PART 2

10 Essential Blood Tests PART 2 Presents 10 Essential Blood Tests PART 2 The Blood Chemistry Webinars With DR. DICKEN WEATHERBY Creator of the Blood Chemistry Software Heart Disease, Inflammation, & Essential Blood Tests #2 to #4: Fibrinogen,

More information

Bioidentical Hormone Replacement Therapy For Men and Women

Bioidentical Hormone Replacement Therapy For Men and Women Bioidentical Hormone Replacement Therapy For Men and Women Welcome to our Aesthetic Medicine practice where we will be introducing our clients to bioidentical hormone replacement. The simplest definition

More information

Sexual Health History: Talking Sex with Gender Non-Conforming & Trans Patients

Sexual Health History: Talking Sex with Gender Non-Conforming & Trans Patients Sexual Health History: Talking Sex with Gender Non-Conforming & Trans Patients Timothy Cavanaugh, MD Co-Medical Director of the Fenway Trans Health Program Fenway Health Continuing Medical Education Disclosure

More information

HIV Epidemiology, LGBT Health Disparities: Implications for Clinical Practice

HIV Epidemiology, LGBT Health Disparities: Implications for Clinical Practice HIV Epidemiology, LGBT Health Disparities: Implications for Clinical Practice April 23, 2013 Harvey Makadon, MD Director, The National LGBT Health Education Center Clinical Professor of Medicine, Harvard

More information

ANDROGEN DEFICIENCY A GUIDE TO MALE HORMONES A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM

ANDROGEN DEFICIENCY A GUIDE TO MALE HORMONES A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM ANDROGEN DEFICIENCY A GUIDE TO MALE HORMONES A BOOKLET IN THE SERIES OF CONSUMER GUIDES ON MALE REPRODUCTIVE HEALTH FROM First published in July 2003 by Andrology Australia 5th Edition, December 2015 Copyright

More information

Recognizing and Managing Testosterone Deficiency

Recognizing and Managing Testosterone Deficiency Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships

More information

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes

More information

Prescriber and Pharmacy Guide for the Tracleer REMS Program

Prescriber and Pharmacy Guide for the Tracleer REMS Program Prescriber and Pharmacy Guide for the Tracleer REMS Program Please see accompanying full Prescribing Information, including BOXED WARNING for hepatotoxicity and teratogenicity. Introduction to Tracleer

More information

Clinical Policy: Gender Reassignment Surgery Reference Number: CP.MP.HN 496

Clinical Policy: Gender Reassignment Surgery Reference Number: CP.MP.HN 496 Clinical Policy: Reference Number: CP.MP.HN 496 Effective Date: 11/09 Last Review Date: 1/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

OBSTETRICS & GYNECOLOGY

OBSTETRICS & GYNECOLOGY JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Female Sexual Arousal

More information

PATIENT INFORMATION LEAFLET. Testosterone Enantate 250mg/ ml Solution for Injection Testosterone Enantate

PATIENT INFORMATION LEAFLET. Testosterone Enantate 250mg/ ml Solution for Injection Testosterone Enantate PATIENT INFORMATION LEAFLET Testosterone Enantate 250mg/ ml Solution for Injection Testosterone Enantate Read all of this leaflet carefully before you start using this medicine because it contains important

More information

Reduce Your Risk of Stroke Starting Now

Reduce Your Risk of Stroke Starting Now Reduce Your Risk of Stroke Starting Now Take steps against recurrent stroke by making the necessary changes in your life. Stroke prevention tips for better health Prevent stroke. Live healthy. You can

More information

Chapter 28: REPRODUCTIVE SYSTEM: MALE

Chapter 28: REPRODUCTIVE SYSTEM: MALE Chapter 28: REPRODUCTIVE SYSTEM: MALE I. FUNCTIONAL ANATOMY (Fig. 28.1) A. Testes: glands which produce male gametes, as well as glands producing testosterone 2. Seminiferous tubules (Fig.28.3; 28.5) a.

More information

Clinical Policy: Implantable Hormone Pellets Reference Number: CA.CP.MP.507

Clinical Policy: Implantable Hormone Pellets Reference Number: CA.CP.MP.507 Clinical Policy: Reference Number: CA.CP.MP.507 Effective Date: 1/12 Last Review Date: 7/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

The Monash Gender Dysphoria Clinic aims to assist clients experiencing Gender Dysphoria through:

The Monash Gender Dysphoria Clinic aims to assist clients experiencing Gender Dysphoria through: Gender Dysphoria Clinic 352 South Road Hampton East VIC 3188 Tel: (03) 9556 5216 (Tuesday & Wednesday ONLY) Fax: (03) 9556 5256 Email: genderclinic@monashhealth.org Web: www.monashhealth.org/page/gender_dysphoria

More information

SALIVA HORMONE TESTING. Nufem and EndoPure

SALIVA HORMONE TESTING. Nufem and EndoPure SALIVA HORMONE TESTING Saliva testing is performed by an independent CLIA licensed laboratory. The key to balancing hormones starts with a NuFem salivary test, which will assess current hormone levels

More information

Clinical Diabetes and Endocrinology in 2017 Pre and Post Test Questions

Clinical Diabetes and Endocrinology in 2017 Pre and Post Test Questions 1) A 24 year old woman has experienced weakness, light headedness and 6 lb weight loss over the past 6 months. Her past history is unremarkable. Vital Signs: BP 90/65, Pulse 80, T 98.3. PE: skin appears

More information

Early or late childhood? Age driven. LH driven Start testosterone when LH begins to rise Indicates that the pituitary is trying and failing

Early or late childhood? Age driven. LH driven Start testosterone when LH begins to rise Indicates that the pituitary is trying and failing Philip S. Zeitler MD. PhD Division of Endocrinology Children s Hospital Colorado Aurora, Colorado Primary testicular failure Central hormones responsible for onset of puberty are normal The testis itself

More information

Spironolactone used for acne side effects

Spironolactone used for acne side effects Spironolactone used for acne side effects Search Aldactone ( spironolactone ) can be used to treat hormonal acne in women. Learn how spironolactone works, and if it's the right treatment for you. Spironolactone

More information

5. Summary of Data Reported and Evaluation

5. Summary of Data Reported and Evaluation 168 IARC MONOGRAPHS VOLUME 91 5. Summary of Data Reported and Evaluation 5.1 Exposure data The first oral hormonal contraceptives that were found to inhibit both ovulation and implantation were developed

More information

Chapter 8.2 The Endocrine System

Chapter 8.2 The Endocrine System Major Endocrine Organs Hypothalamus Pineal Gland Pituitary Gland Thyroid Gland Thymus Gland Adrenal Glands Pancreas Ovaries (Female) Testis (Male) Chapter 8.2 The Endocrine System The endocrine system

More information

Family Building for Transgender Men and Women

Family Building for Transgender Men and Women Family Building for Transgender Men and Women A Guide to Becoming a Parent PATH2PARENTHOOD path2parenthood.org Are you a transgender man or woman and think you might want to become a parent? If you re

More information

Hormonal Treatment of Acne and Hirsutism. Julie C Harper MD

Hormonal Treatment of Acne and Hirsutism. Julie C Harper MD Hormonal Treatment of Acne and Hirsutism Julie C Harper MD none Conflict of Interest Hormonal treatments Combination oral contraceptives Oral antiandrogens Spironolactone Cyproterone acetate Finasteride

More information

Hormone Treatments and the Risk of Breast Cancer

Hormone Treatments and the Risk of Breast Cancer Cornell University Program on Breast Cancer and Environmental Risk Factors in New York State (BCERF) Updated July 2002 Hormone Treatments and the Risk of Breast Cancer 1) Hormone Treatment After Menopause

More information

Endocrine Glands System. Agha Zohaib Khan

Endocrine Glands System. Agha Zohaib Khan Endocrine Glands System Agha Zohaib Khan Introduction Endocrine means secreting internally. Indeed, the endocrine system is made up of glands whose secretions enter the blood stream. Hence these glands

More information

2. What you need to know before you use TESTOGEL

2. What you need to know before you use TESTOGEL TESTOGEL 50 mg, gel in sachet Testosterone Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to

More information

Bioidentical Hormone Preparations - History of Development

Bioidentical Hormone Preparations - History of Development Bioidentical Hormone Preparations - History of Development The use of the terminology BIOIDENTICAL HORMONE therapy has aroused much controversy and heated debate over the past 20 years, often with much

More information

Table of Contents. What Is Hypopituitarism? What Causes Hypopituitarism? What It Means to You... 4

Table of Contents. What Is Hypopituitarism? What Causes Hypopituitarism? What It Means to You... 4 Hypopituitarism Table of Contents What Is Hypopituitarism?... 2 What Causes Hypopituitarism?... 4 What It Means to You... 4 I. Thyroid-Stimulating Hormone (TSH) Deficiency... 4 II. Adrenocorticotrophic

More information